Stuti Girish Shroff, Ph.D., M.B.,B.S.
Concepts are derived automatically from a person's publications.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
| Name | Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Puerperal Disorders | 1 | 2022 | 282 | 0.750 |
Why?
|
| Glomerulonephritis, IGA | 1 | 2017 | 63 | 0.630 |
Why?
|
| Common Bile Duct Neoplasms | 2 | 2014 | 113 | 0.600 |
Why?
|
| Ampulla of Vater | 2 | 2014 | 141 | 0.590 |
Why?
|
| Abdominal Pain | 1 | 2022 | 1026 | 0.580 |
Why?
|
| Intestinal Neoplasms | 1 | 2017 | 297 | 0.550 |
Why?
|
| Fever | 1 | 2022 | 1586 | 0.540 |
Why?
|
| Sarcoma, Kaposi | 1 | 2017 | 362 | 0.530 |
Why?
|
| SOX9 Transcription Factor | 1 | 2013 | 152 | 0.460 |
Why?
|
| Barrett Esophagus | 3 | 2023 | 488 | 0.450 |
Why?
|
| Immunocompromised Host | 1 | 2017 | 867 | 0.440 |
Why?
|
| Pancreatic Ducts | 1 | 2013 | 333 | 0.430 |
Why?
|
| Carcinoma, Pancreatic Ductal | 3 | 2021 | 1510 | 0.420 |
Why?
|
| Adenocarcinoma | 8 | 2022 | 6324 | 0.420 |
Why?
|
| Esophageal Neoplasms | 4 | 2023 | 1509 | 0.390 |
Why?
|
| Arteries | 4 | 1997 | 1084 | 0.320 |
Why?
|
| PTEN Phosphohydrolase | 1 | 2013 | 1162 | 0.320 |
Why?
|
| Neuroendocrine Tumors | 3 | 2018 | 533 | 0.300 |
Why?
|
| Colonic Neoplasms | 3 | 2022 | 2532 | 0.290 |
Why?
|
| Crohn Disease | 1 | 2017 | 2256 | 0.270 |
Why?
|
| Pancreatic Neoplasms | 3 | 2021 | 4981 | 0.270 |
Why?
|
| Adenocarcinoma, Mucinous | 2 | 2022 | 485 | 0.260 |
Why?
|
| Stomach Neoplasms | 4 | 2020 | 1245 | 0.260 |
Why?
|
| Cell Lineage | 1 | 2013 | 2594 | 0.250 |
Why?
|
| Models, Cardiovascular | 4 | 1997 | 1002 | 0.230 |
Why?
|
| Polyendocrinopathies, Autoimmune | 1 | 2022 | 55 | 0.220 |
Why?
|
| Ventricular Function, Left | 4 | 1999 | 3365 | 0.210 |
Why?
|
| Nerve Tissue | 1 | 2021 | 75 | 0.200 |
Why?
|
| Carcinoma | 2 | 2022 | 2320 | 0.200 |
Why?
|
| Carotid Body Tumor | 1 | 2020 | 32 | 0.200 |
Why?
|
| Bile Acids and Salts | 1 | 2022 | 355 | 0.190 |
Why?
|
| Radiation-Sensitizing Agents | 1 | 2021 | 385 | 0.180 |
Why?
|
| Neck Dissection | 1 | 2020 | 216 | 0.170 |
Why?
|
| Albumins | 1 | 2021 | 564 | 0.170 |
Why?
|
| Paraganglioma | 1 | 2020 | 147 | 0.170 |
Why?
|
| Gastritis, Atrophic | 1 | 2018 | 31 | 0.170 |
Why?
|
| p38 Mitogen-Activated Protein Kinases | 1 | 2021 | 722 | 0.160 |
Why?
|
| Colonic Polyps | 1 | 2022 | 519 | 0.160 |
Why?
|
| Neoplasms, Multiple Primary | 2 | 2020 | 623 | 0.160 |
Why?
|
| Acidosis | 1 | 1999 | 272 | 0.160 |
Why?
|
| Lithotripsy, Laser | 1 | 1996 | 44 | 0.150 |
Why?
|
| Extracellular Space | 1 | 1999 | 606 | 0.150 |
Why?
|
| Postpartum Period | 1 | 2022 | 990 | 0.150 |
Why?
|
| Inhibins | 1 | 2017 | 226 | 0.150 |
Why?
|
| Laryngeal Neoplasms | 1 | 2020 | 540 | 0.150 |
Why?
|
| Cytogenetic Analysis | 1 | 2017 | 306 | 0.140 |
Why?
|
| Adenomatous Polyps | 1 | 2017 | 109 | 0.140 |
Why?
|
| Ureteral Calculi | 1 | 1996 | 103 | 0.140 |
Why?
|
| Myocardial Contraction | 2 | 1999 | 1639 | 0.140 |
Why?
|
| Diarrhea | 1 | 2022 | 1372 | 0.130 |
Why?
|
| Iatrogenic Disease | 1 | 2017 | 527 | 0.130 |
Why?
|
| Receptor, Notch1 | 1 | 2017 | 519 | 0.130 |
Why?
|
| Liver Neoplasms | 2 | 2022 | 4102 | 0.130 |
Why?
|
| Paclitaxel | 1 | 2021 | 1626 | 0.130 |
Why?
|
| Fatty Acids | 1 | 2021 | 1748 | 0.120 |
Why?
|
| Pancreaticoduodenectomy | 2 | 2014 | 502 | 0.120 |
Why?
|
| Prednisone | 1 | 2017 | 1546 | 0.120 |
Why?
|
| Receptors, Notch | 1 | 2017 | 754 | 0.110 |
Why?
|
| Colorectal Neoplasms | 2 | 2022 | 6592 | 0.110 |
Why?
|
| 14-alpha Demethylase Inhibitors | 1 | 2011 | 4 | 0.110 |
Why?
|
| Hepatitis C | 1 | 2022 | 1521 | 0.110 |
Why?
|
| Fructose-Bisphosphate Aldolase | 1 | 2011 | 55 | 0.110 |
Why?
|
| Cyclin D1 | 1 | 2014 | 468 | 0.110 |
Why?
|
| Clotrimazole | 1 | 2011 | 77 | 0.110 |
Why?
|
| Adenoma | 1 | 2022 | 2119 | 0.110 |
Why?
|
| Tissue Array Analysis | 1 | 2013 | 573 | 0.110 |
Why?
|
| Aorta | 3 | 1997 | 2076 | 0.110 |
Why?
|
| Molecular Diagnostic Techniques | 1 | 2017 | 622 | 0.110 |
Why?
|
| Cholangiocarcinoma | 1 | 2017 | 525 | 0.100 |
Why?
|
| Bile Duct Neoplasms | 1 | 2017 | 579 | 0.100 |
Why?
|
| Liver Cirrhosis | 1 | 2021 | 1757 | 0.100 |
Why?
|
| Forkhead Transcription Factors | 3 | 2022 | 1597 | 0.100 |
Why?
|
| Resuscitation | 1 | 1995 | 640 | 0.100 |
Why?
|
| Rabbits | 4 | 1999 | 5060 | 0.100 |
Why?
|
| Carcinoma, Hepatocellular | 1 | 2022 | 2091 | 0.100 |
Why?
|
| Immunohistochemistry | 4 | 2021 | 11689 | 0.090 |
Why?
|
| Liver Transplantation | 1 | 2020 | 2019 | 0.090 |
Why?
|
| Gene Expression Profiling | 3 | 2021 | 9504 | 0.090 |
Why?
|
| Neoadjuvant Therapy | 1 | 2020 | 2556 | 0.090 |
Why?
|
| Shock, Septic | 1 | 1995 | 726 | 0.090 |
Why?
|
| Stroke Volume | 2 | 1999 | 4487 | 0.080 |
Why?
|
| Carcinoma, Papillary | 1 | 2013 | 793 | 0.080 |
Why?
|
| Proto-Oncogene Proteins B-raf | 3 | 2022 | 1941 | 0.080 |
Why?
|
| Anti-Inflammatory Agents | 1 | 2017 | 1785 | 0.080 |
Why?
|
| Humans | 29 | 2023 | 715818 | 0.080 |
Why?
|
| Hydroxymethylglutaryl-CoA Reductase Inhibitors | 1 | 2022 | 3149 | 0.080 |
Why?
|
| Gastrointestinal Stromal Tumors | 1 | 2013 | 665 | 0.080 |
Why?
|
| Disease-Free Survival | 2 | 2017 | 7015 | 0.070 |
Why?
|
| Blood Volume | 2 | 1999 | 587 | 0.070 |
Why?
|
| Cell Transformation, Neoplastic | 1 | 2017 | 2985 | 0.070 |
Why?
|
| Early Detection of Cancer | 1 | 2020 | 2939 | 0.070 |
Why?
|
| Autoimmune Diseases | 1 | 2018 | 2100 | 0.070 |
Why?
|
| Fluorouracil | 2 | 2021 | 1610 | 0.070 |
Why?
|
| Male | 17 | 2022 | 350352 | 0.070 |
Why?
|
| Tumor Suppressor Protein p53 | 3 | 2023 | 2946 | 0.070 |
Why?
|
| Female | 17 | 2022 | 377229 | 0.070 |
Why?
|
| Diagnosis, Differential | 3 | 2017 | 13219 | 0.060 |
Why?
|
| Adult | 11 | 2022 | 212279 | 0.060 |
Why?
|
| Blood Pressure | 2 | 1996 | 8544 | 0.060 |
Why?
|
| Agrin | 1 | 2022 | 42 | 0.060 |
Why?
|
| Kaplan-Meier Estimate | 1 | 2013 | 6730 | 0.060 |
Why?
|
| Vascular Resistance | 2 | 1995 | 949 | 0.060 |
Why?
|
| Endometrial Neoplasms | 1 | 2011 | 1343 | 0.050 |
Why?
|
| MutS Homolog 2 Protein | 1 | 2022 | 192 | 0.050 |
Why?
|
| Micelles | 1 | 2022 | 205 | 0.050 |
Why?
|
| Prognosis | 3 | 2022 | 29007 | 0.050 |
Why?
|
| Genetic Predisposition to Disease | 2 | 2020 | 17409 | 0.050 |
Why?
|
| Registries | 1 | 2017 | 8048 | 0.050 |
Why?
|
| Middle Aged | 12 | 2021 | 214666 | 0.050 |
Why?
|
| Disease Progression | 4 | 2021 | 13215 | 0.050 |
Why?
|
| Tumor Microenvironment | 2 | 2022 | 3054 | 0.050 |
Why?
|
| Coloring Agents | 1 | 2023 | 551 | 0.050 |
Why?
|
| Permeability | 1 | 2022 | 786 | 0.050 |
Why?
|
| Hoarseness | 1 | 2020 | 63 | 0.050 |
Why?
|
| Liver Function Tests | 1 | 2021 | 534 | 0.050 |
Why?
|
| Aged, 80 and over | 5 | 2021 | 58326 | 0.050 |
Why?
|
| Compliance | 2 | 1997 | 106 | 0.050 |
Why?
|
| DNA Mismatch Repair | 1 | 2022 | 408 | 0.040 |
Why?
|
| Mucins | 1 | 2022 | 552 | 0.040 |
Why?
|
| Diagnostic Imaging | 1 | 2013 | 3494 | 0.040 |
Why?
|
| Leucovorin | 1 | 2020 | 596 | 0.040 |
Why?
|
| Organ Preservation | 1 | 2020 | 279 | 0.040 |
Why?
|
| Biopsy | 2 | 2023 | 6737 | 0.040 |
Why?
|
| Computational Biology | 2 | 2021 | 3571 | 0.040 |
Why?
|
| Aged | 8 | 2021 | 162468 | 0.040 |
Why?
|
| Young Adult | 3 | 2020 | 56228 | 0.040 |
Why?
|
| Deoxycytidine | 1 | 2021 | 825 | 0.040 |
Why?
|
| Metaplasia | 1 | 2018 | 311 | 0.040 |
Why?
|
| Vasomotor System | 1 | 1997 | 212 | 0.040 |
Why?
|
| Gastroscopy | 1 | 2018 | 199 | 0.040 |
Why?
|
| Lymphocytes, Tumor-Infiltrating | 1 | 2022 | 1046 | 0.040 |
Why?
|
| Perfusion | 1 | 2020 | 1273 | 0.040 |
Why?
|
| Mathematics | 1 | 1997 | 745 | 0.040 |
Why?
|
| Smad4 Protein | 1 | 2017 | 166 | 0.040 |
Why?
|
| Treatment Outcome | 5 | 2021 | 62040 | 0.040 |
Why?
|
| Liver | 2 | 2022 | 7594 | 0.030 |
Why?
|
| Cardiovascular Physiological Phenomena | 1 | 1997 | 245 | 0.030 |
Why?
|
| Pressure | 1 | 1999 | 1234 | 0.030 |
Why?
|
| Nitroprusside | 1 | 1995 | 285 | 0.030 |
Why?
|
| Diastole | 1 | 1997 | 816 | 0.030 |
Why?
|
| Ligands | 1 | 2022 | 3294 | 0.030 |
Why?
|
| Hemodynamics | 2 | 1995 | 4214 | 0.030 |
Why?
|
| Animals | 7 | 2022 | 169404 | 0.030 |
Why?
|
| Tumor Burden | 1 | 2020 | 1900 | 0.030 |
Why?
|
| Disease Susceptibility | 1 | 2021 | 1780 | 0.030 |
Why?
|
| Hepatocytes | 1 | 2021 | 1238 | 0.030 |
Why?
|
| Proportional Hazards Models | 2 | 2021 | 12460 | 0.030 |
Why?
|
| Gastrectomy | 1 | 2018 | 548 | 0.030 |
Why?
|
| Elasticity | 1 | 1995 | 655 | 0.030 |
Why?
|
| Vasodilation | 1 | 1997 | 957 | 0.030 |
Why?
|
| Proto-Oncogene Proteins c-akt | 1 | 2022 | 2555 | 0.030 |
Why?
|
| Esophagectomy | 1 | 2017 | 459 | 0.030 |
Why?
|
| ROC Curve | 1 | 2021 | 3525 | 0.030 |
Why?
|
| Cyclin-Dependent Kinase Inhibitor p21 | 1 | 2014 | 374 | 0.030 |
Why?
|
| Epithelial-Mesenchymal Transition | 1 | 2017 | 714 | 0.030 |
Why?
|
| Endotoxins | 1 | 1995 | 560 | 0.030 |
Why?
|
| Neoplasm Invasiveness | 1 | 2021 | 3681 | 0.030 |
Why?
|
| Stress, Mechanical | 1 | 1997 | 1684 | 0.030 |
Why?
|
| Neoplasms | 1 | 2021 | 20528 | 0.030 |
Why?
|
| Vasoconstriction | 1 | 1995 | 603 | 0.030 |
Why?
|
| Fatal Outcome | 1 | 2017 | 1879 | 0.030 |
Why?
|
| Neoplasm Staging | 2 | 2020 | 11145 | 0.030 |
Why?
|
| Regional Blood Flow | 1 | 1995 | 1558 | 0.030 |
Why?
|
| Biopsy, Needle | 1 | 2017 | 1673 | 0.030 |
Why?
|
| Statistics, Nonparametric | 1 | 2017 | 2951 | 0.020 |
Why?
|
| Gene Expression Regulation, Neoplastic | 2 | 2021 | 8571 | 0.020 |
Why?
|
| Precancerous Conditions | 1 | 2017 | 946 | 0.020 |
Why?
|
| Mesoderm | 1 | 2013 | 723 | 0.020 |
Why?
|
| Dogs | 1 | 1995 | 4045 | 0.020 |
Why?
|
| Catheterization | 1 | 1995 | 1449 | 0.020 |
Why?
|
| Adolescent | 4 | 2020 | 85157 | 0.020 |
Why?
|
| Retrospective Studies | 2 | 2017 | 72473 | 0.020 |
Why?
|
| Stomach | 1 | 2013 | 670 | 0.020 |
Why?
|
| Terminology as Topic | 1 | 2017 | 1612 | 0.020 |
Why?
|
| Chronic Disease | 1 | 2022 | 9034 | 0.020 |
Why?
|
| Proto-Oncogene Proteins c-bcl-2 | 1 | 2014 | 1369 | 0.020 |
Why?
|
| Gene Expression Regulation, Enzymologic | 1 | 2011 | 1255 | 0.020 |
Why?
|
| Head and Neck Neoplasms | 1 | 2020 | 2719 | 0.020 |
Why?
|
| Academic Medical Centers | 1 | 2017 | 2790 | 0.020 |
Why?
|
| Rats | 1 | 2022 | 24852 | 0.020 |
Why?
|
| Antihypertensive Agents | 1 | 1995 | 2058 | 0.020 |
Why?
|
| Follow-Up Studies | 2 | 2017 | 39305 | 0.020 |
Why?
|
| Stents | 1 | 1996 | 3212 | 0.020 |
Why?
|
| Models, Biological | 1 | 2021 | 9809 | 0.020 |
Why?
|
| Reverse Transcriptase Polymerase Chain Reaction | 1 | 2011 | 4893 | 0.020 |
Why?
|
| Survival Analysis | 1 | 2017 | 10503 | 0.020 |
Why?
|
| Length of Stay | 1 | 1996 | 6270 | 0.010 |
Why?
|
| Gene Expression Regulation | 1 | 2021 | 12305 | 0.010 |
Why?
|
| Disease Models, Animal | 1 | 2021 | 18197 | 0.010 |
Why?
|
| Cell Survival | 1 | 2011 | 6035 | 0.010 |
Why?
|
| Predictive Value of Tests | 1 | 2017 | 15198 | 0.010 |
Why?
|
| Contrast Media | 1 | 2013 | 5276 | 0.010 |
Why?
|
| Cross-Sectional Studies | 1 | 2020 | 23437 | 0.010 |
Why?
|
| Phenotype | 1 | 2017 | 16311 | 0.010 |
Why?
|
| Antineoplastic Combined Chemotherapy Protocols | 1 | 2020 | 11236 | 0.010 |
Why?
|
| Time Factors | 2 | 1999 | 40887 | 0.010 |
Why?
|
| Polymorphism, Single Nucleotide | 1 | 2017 | 15603 | 0.010 |
Why?
|
| Tomography, X-Ray Computed | 1 | 2020 | 20357 | 0.010 |
Why?
|
| Pulsatile Flow | 1 | 1997 | 335 | 0.010 |
Why?
|
| RNA, Messenger | 1 | 2011 | 13212 | 0.010 |
Why?
|
| Pregnancy | 1 | 1997 | 27398 | 0.010 |
Why?
|
| Hypertension | 1 | 1995 | 8270 | 0.010 |
Why?
|
| Risk Assessment | 1 | 2017 | 23476 | 0.010 |
Why?
|
| Atenolol | 1 | 1995 | 102 | 0.010 |
Why?
|
| Nifedipine | 1 | 1995 | 218 | 0.010 |
Why?
|
| Ramipril | 1 | 1995 | 76 | 0.010 |
Why?
|
| Mice | 1 | 2021 | 80373 | 0.010 |
Why?
|
| Signal Transduction | 1 | 2017 | 23729 | 0.010 |
Why?
|
| Echocardiography | 2 | 1997 | 5045 | 0.010 |
Why?
|
| Blood Flow Velocity | 1 | 1997 | 1438 | 0.010 |
Why?
|
| Magnetic Resonance Imaging | 1 | 2020 | 34430 | 0.010 |
Why?
|
| Ultrasonography, Doppler | 1 | 1995 | 456 | 0.010 |
Why?
|
| Risk Factors | 1 | 2018 | 70879 | 0.010 |
Why?
|
| Reference Values | 1 | 1997 | 5050 | 0.010 |
Why?
|
| Cross-Over Studies | 1 | 1995 | 2015 | 0.010 |
Why?
|
| Administration, Oral | 1 | 1995 | 3955 | 0.000 |
Why?
|
| Analysis of Variance | 1 | 1995 | 6502 | 0.000 |
Why?
|
| Double-Blind Method | 1 | 1995 | 11945 | 0.000 |
Why?
|